CStone Reports 2024 Interim Results and Recent Corporate Updates
- Written by PR Newswire
- Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve at RMB 814 million as of June 30, 2024.
- NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful international approval of a China domestic anti-PD-L1 mAb.
- Partnered with Ewopharma for sugemalimab commercialization...
Read more: CStone Reports 2024 Interim Results and Recent Corporate Updates














